Eli Lilly and Company · Healthcare
Paid for today, but breaks on a small cut — or only looks over-priced at a 9% discount rate.
At a 36.0% margin the price requires 14.7% 3y revenue CAGR against 23.1% consensus, a cushion of -0.2pt versus a 0pt correction cut. Cushion is negative at the panel margin but turns positive 1pt lower in the discount rate, so it hangs on the rate and the margin. Mega-cap momentum de-rating, not a business channel.
Would recover if: realized-price erosion (Q3 2026-11-04) outruns volume growth. We re-check this against analyst estimates every evening.
10 years, at a 36% margin (analysts' margin, cut for cash conversion)
+14.6%/yr over 10 years once faded to terminal growth
points off 3-year analyst growth
20 published targets, set before the drop
Linked to AMZN, NVDA
Does the profit analysts build their margin on actually arrive as cash? Measured over the last 3 annual statements filed before this test. After stock-based pay, 77% of reported profit arrived as operating cash, so the test cuts the analysts' 43% margin to 33%. That leaves a cushion of −2pt instead of +4pt, and the smaller of the two decides the group.
How much of reported profit arrived as operating cash. Below 0.8× is a red flag.
Profit not backed by cash, as a share of assets, latest year. Above 10% is a red flag.
Staff paid in shares instead of cash, which flatters margins. Above 10% is a red flag.
Dilution of each share's claim on the business. Above 3% a year is a red flag.
Non-operating gains in the latest year. Above 25% is a red flag.
After capex. Shown for context: heavy investment is not bad earnings, so it is never solved under.
From the priced-in reconstruction of Sep 10, 2026. Its figures use that day's price and free-cash-flow margin, so they can differ from the stress test above.
The price sits at the 10th percentile of published models, leaning bearish against the street by rejecting the bull case for sustained GLP-1 dominance that 14 banks endorse, while accepting a path that requires revenue growth to decelerate sharply from 44.7% to roughly 30%.
Whether GLP-1 demand and Eli Lilly's production capacity can sustain growth closer to 35% rather than the 30% the price requires — and while unit volumes are wired and can confirm the trajectory, pricing power and prescription persistence remain unmeasurable with available tools.
What the price refuses to pay for, and the full reconstruction, on the LLY quote page →A stress test of whether this narrative is still paid for by analyst forecasts, not a forecast that the stock will rise. The price-implied growth on its own has not predicted returns in our testing, and this list (sealed Nov 21, 2026) has not been graded yet. Cut sizes are assumptions. Not investment advice. Back to all names